Acetazolamide for Treatment Resistant Schizophrenia
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
Vishwajit Nimgaonkar, MD PhD
60 participants
Feb 1, 2022
INTERVENTIONAL
Conditions
Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Identical gelatin capsules will be prepared by filling with inert excipients.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04887792